BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced...
...Parkinson’s disease and Alzheimer’s disease.AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and 3SBio Inc. (HKEX:1530; Shanghai:688336) market Byetta exenatide...
...of Medicine, Philadelphia, Pa.email: jacob.sterling@pennmedicine.upenn.eduCONTACT: Qi N. Cui, same affiliation as aboveemail: qi.cui@pennmedicine.upenn.edu Claire Quang NLY01 (pegylated exenatide) University...
BioCentury | Mar 11, 2020
Regulation

Intarcia’s path uncertain after second regulatory stumble for diabetes implant

...the known GLP-1R agonist exenatide, marketed by AstraZeneca plc (LSE:AZN; NYSE:AZN) in other formulations as Byetta...
BioCentury | Oct 8, 2019
Company News

After remedies to NDA, Intarcia’s diabetes implant under FDA review again

...is back under the agency’s review. The new PDUFA date for ITCA 650, which delivers exenatide...
...Luxin Venture Capital Group Co. Ltd. (Shanghai:600783). AstraZeneca plc (LSE:AZN; NYSE:AZN) markets twice-daily exenatide as Byetta...
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...a note that drugs such as CSPC’s cancer drug Duomeisu doxorubicin, 3SBio diabetes drug Bydureon exenatide...
BioCentury | Mar 5, 2019
Company News

Intarcia licenses Numab's autoimmune therapy

...letter for the product. Details were not disclosed. ITCA 650 provides continuous subcutaneous delivery of exenatide...
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...extension of CV benefit for its SGLT2 inhibitor Farxiga dapagliflozin and its GLP-1R agonist Bydureon exenatide...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Endocrine/metabolic

...the same model, the mAb plus the GLP-1R agonists Victoza liraglutide, Trulicity dulaglutide or Byetta exenatide...
...Sumitomo Dainippon Pharma Co. Ltd. market Trulicity for diabetes. AstraZeneca plc and 3SBio Inc. market Byetta...
...doi:10.1126/scitranslmed.aat3392 CONTACT: David J. Lloyd, Amgen Inc., Thousand Oaks, Calif. email: dlloyd@amgen.com Claire Quang Byetta, exenatide (AC2993, Exendin-4) GLP-1Fc...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

...greater efficacy than the GLP-1 molecule used by Lilly, which is based on the Byetta exenatide...
BioCentury | Nov 9, 2018
Distillery Techniques

Chemistry; drug platforms

...final product, or to link additional functional groups to the ion. When applied to Byetta exenatide...
...peptides/proteins in less than five minutes with yields of up to 95%. When applied to Byetta...
...2018 doi:10.1038/s41586-018-0608-y CONTACT: Matthew Gaunt, University of Cambridge, Cambridge, U.K. email: mjg32@cam.ac.uk Allison Johnson Byetta, exenatide (AC2993, Exendin-4) University...
BioCentury | Nov 6, 2018
Distillery Techniques

Drug delivery

...a GLP-1R agonist construct composed of peptide sequences from human glucagon-like peptide-1 (GLP-1) and Byetta exenatide...
...efficacy and safety of the conjugates in models of Type II diabetes. AstraZeneca plc markets Byetta...
Items per page:
1 - 10 of 775